Literature DB >> 24075228

A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa.

Supriya S Venugopal1, Wenfei Yan, John W Frew, Heather I Cohn, Lesley M Rhodes, Kim Tran, Wei Melbourne, Janis A Nelson, Marian Sturm, Janice Fogarty, M Peter Marinkovich, Satomi Igawa, Akemi Ishida-Yamamoto, Dedee F Murrell.   

Abstract

BACKGROUND: Chronic wounds are a major source of morbidity and mortality in generalized severe recessive dystrophic epidermolysis bullosa (RDEB-GS).
OBJECTIVE: This was a phase II double-blinded randomized controlled trial of intralesional allogeneic cultured fibroblasts in suspension solution versus suspension solution alone for wound healing in RDEB-GS.
METHODS: Adult patients with RDEB-GS were screened for chronic ulcers and reduced collagen VII expression. Up to 6 pairs of symmetric wounds were measured and biopsied at baseline, then randomized to cultured allogeneic fibroblasts in a crystalloid suspension solution with 2% albumin or suspension solution alone. Ulcer size, collagen VII protein and messenger RNA expression, anchoring fibril numbers, morphology, and inflammatory markers were measured at 2 weeks and at 3, 6, and 12 months.
RESULTS: All wounds healed significantly more rapidly with fibroblasts and vehicle injections, with an area decrease of 50% by 12 weeks, compared with noninjected wounds. Collagen VII expression increased to a similar degree in both study arms in wounds from 3 of 5 patients. LIMITATIONS: The number of patients with RDEB-GS who met inclusion criteria was a limitation, as was 1 trial center rather than multicenter.
CONCLUSIONS: The injection of both allogeneic fibroblasts and suspension solution alone improved wound healing in chronic nonhealing RDEB-GS wounds independently of collagen VII regeneration. This may provide feasible therapy for wound healing in patients with RDEB-GS.
Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  EB; HLA; RDEB; RDEB-GS; VAS; allogeneic fibroblasts; cell therapy; collagen VII; epidermolysis bullosa; generalized severe recessive dystrophic epidermolysis bullosa; injections; mRNA; messenger RNA; phase II; quality of life; randomized controlled trial; recessive dystrophic epidermolysis bullosa; visual analog scale; wound healing

Mesh:

Year:  2013        PMID: 24075228     DOI: 10.1016/j.jaad.2013.08.014

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  36 in total

1.  From Mesoderm to Mesodermatology: Bone Marrow Mesenchymal Cells Heal Skin Wounds.

Authors:  Marketa Tolarova; Jakub Tolar
Journal:  Mol Ther       Date:  2015-08       Impact factor: 11.454

2.  Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa.

Authors:  Gabriela Petrof; Su M Lwin; Magdalena Martinez-Queipo; Alya Abdul-Wahab; Simon Tso; Jemima E Mellerio; Ineke Slaper-Cortenbach; Jaap J Boelens; Jakub Tolar; Paul Veys; Mercy Ofuya; Janet L Peacock; Anna E Martinez; John A McGrath
Journal:  J Invest Dermatol       Date:  2015-04-23       Impact factor: 8.551

3.  High Local Concentrations of Intradermal MSCs Restore Skin Integrity and Facilitate Wound Healing in Dystrophic Epidermolysis Bullosa.

Authors:  Tobias Kühl; Markus Mezger; Ingrid Hausser; Rupert Handgretinger; Leena Bruckner-Tuderman; Alexander Nyström
Journal:  Mol Ther       Date:  2015-04-10       Impact factor: 11.454

Review 4.  Recessive Dystrophic Epidermolysis Bullosa: Advances in the Laboratory Leading to New Therapies.

Authors:  David T Woodley; Mei Chen
Journal:  J Invest Dermatol       Date:  2015-07       Impact factor: 8.551

Review 5.  From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.

Authors:  Beau R Webber; Jakub Tolar
Journal:  Mol Ther       Date:  2015-03-24       Impact factor: 11.454

6.  Gene Therapy for Epidermolysis Bullosa: Sticky Business.

Authors:  Alexander Nyström; Leena Bruckner-Tuderman
Journal:  Mol Ther       Date:  2016-12       Impact factor: 11.454

7.  Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients.

Authors:  David T Woodley; Jon Cogan; Yingping Hou; Chao Lyu; M Peter Marinkovich; Douglas Keene; Mei Chen
Journal:  J Clin Invest       Date:  2017-07-10       Impact factor: 14.808

8.  Local Expression of Indoleamine 2,3, Dioxygenase Prolongs Allogenic Skin Graft Take in a Mouse Model.

Authors:  Mohammadreza Pakyari; Ali Farokhi; Reza B Jalili; Ruhangiz T Kilani; Erin Brown; Aziz Ghahary
Journal:  Adv Wound Care (New Rochelle)       Date:  2019-02-13       Impact factor: 4.730

Review 9.  Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa.

Authors:  Ellie Rashidghamat; John A McGrath
Journal:  Intractable Rare Dis Res       Date:  2017-02

Review 10.  Cell therapy in dermatology.

Authors:  Gabriela Petrof; Alya Abdul-Wahab; John A McGrath
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-02       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.